Journal of Experimental & Clinical Cancer Research’s Post

🚀 Exciting advancements in #HER2Positive #BreastCancer treatment discussed by VK Gadi, MD PhD and Anne ODea Traditionally, treatments like the Cleopatra regimen—combining trastuzumab, pertuzumab, and docetaxel—have set the standard for HER2-positive breast cancer, boosting survival rates from about 18 months to nearly 6 years. However, these gains often come with significant side effects, including hair loss, bone marrow suppression, neuropathy, and cardiotoxicity. Dr. Gadi and Dr. O'Dea express optimism about new targeted therapies, including TKIs (tyrosine kinase inhibitors) and antibody-drug conjugates (ADCs) like TDXD (trastuzumab deruxtecan), which have the potential to offer more durable responses with fewer toxicities. A new frontline trial is evaluating TDXD against the Cleopatra regimen, and if TDXD delivers sustained, tolerable results, it could become the first-line treatment, reducing or even replacing the need for chemotherapy. They underscore the importance of progression-free survival and treatment sequencing, aiming for a future where HER2-positive breast cancer is managed with targeted options that reduce toxicity and improve quality of life. This could revolutionize the standard of care for patients. #Oncology #CancerResearch #TargetedTherapies #HealthcareInnovation #astrazeneca

Nice retrospective French 🇫🇷 cohort : presented at ESMO 2024 Evaluated 1L with capecitabine improved (OS) compared with (IV) chemotherapy for patients with (ER)-positive HER2-negative metastatic breast cancer following exhaustion of all endocrine treatment, according to real-world data In a multivariable analysis at a median follow-up of 87.2 months, the researchers found that median OS significantly favored the CAPE group (23.6 versus 19.7 months; P = 0.0360). 👏 The researchers noted that OS results were identical for patients who received CDK4/6 inhibitors. NICE DATA agreed with the practice of many oncologists However some important tips to consider: CAPE-treated pts were on average 5 years older, had more often bone metastases only and fewer metastatic sites ( means lower risk group ) 👌 Also, the IV chemotherapy group included different agents with different efficacies So, still needed to be studied in phase III setting with well balanced and homogeneous groups 🧐

🔬 Functional Precision Medicine: Latest Insights  📚Functional precision oncology must beTwo groundbreaking studies shed light on using tumor-derived organoids for precision medicine in colorectal cancer: Ooft et al. (ESMO Open, 2021) conducted a trial on 61 patients, revealing organoid drug sensitivity but no clinical responses. Jensen et al. (J Exp Clin Cancer Res, 2023) studied 90 patients, reporting improved outcomes with individualized treatments based on organoid testing. 🛑Challenges remain, including organoid generation and timely result delivery. 🔮However, upcoming research by Cartry et al. offers promising solutions, paving the way for future clinical trials. 🔗Learn more by reading our latest published article on PDOs in functional precision medicine : Cartry et al. (PMID: 37880806) These findings mark a significant step in advancing personalized cancer care, emphasizing the need for ongoing innovation! #PrecisionMedicine #CancerResearch #OrganoidTechnology #ClinicalTrials

#HenliusMedicalHub 🌍 We are proud to announce that the Phase 2 study results of HLX07, an innovative anti-EGFR monoclonal antibody, have been published in Cancer Communications (Latest Impact Factor: 20.1)! 🎉 Currently, no #EGFR targeted therapies for advanced esophageal squamous cell carcinoma (#ESCC) have been approved globally. 📊 Key Findings from the Study: Combination Therapy (HLX07 + serplulimab + chemotherapy): ORR 60%, PFS 7.8 months, DOR 7.2 months. Monotherapy (HLX07): ORR 15%, PFS 1.5 months, DOR not reached (>6 months). HLX07 shows promising anti-tumor activity and controlled toxicity, providing hope for better treatment outcomes. Henlius is actively advancing Phase 2 trials for HLX07 across multiple indications, including ESCC, squamous cell carcinoma of the skin, and nasopharyngeal carcinoma. Together, we are working to deliver innovative and affordable therapies to patients worldwide. 💡 Learn more: https://lnkd.in/gdGW9Esq https://lnkd.in/giAmKWK6 #CancerResearch #Oncology #HealthcareInnovation #ClinicalTrials

Biomarkers can impact colorectal cancer treatment options. By testing for biomarkers, your medical team can personalize your treatment based on the unique mutations in your tumor, choosing the most effective treatments and helping you avoid unnecessary treatment or side effects. These test results can also connect you with clinical trials testing targeted therapies.    Today, on World mCRC Day, we join our international advocacy partners to raise awareness of metastatic CRC (mCRC) and biomarkers, including the impact biomarkers have on mCRC treatment.     Please visit  https://lnkd.in/eGcbN9xb learn more. #worldmCRCDay #colorectalcancer #coloncancer #bowelcancer 

I had the honor of presenting our latest findings from the #PENELOPE-B trial at #ESMO2024, focusing on high-risk HR+/HER2- breast cancer patients with residual disease after neoadjuvant chemotherapy. In the Penelope-B trial, we tested whether adding palbociclib to standard endocrine therapy could improve #outcomes. 👉 While no significant #overall #survival benefit was seen in the general population, there were exciting trends in patients with invasive #lobular breast cancer, showing improved survival with #palbociclib. 👉 In this subgroup, we observed a notable difference in both overall survival and invasive disease-free survival, emphasizing the potential for more #personalized #treatment strategies based on #tumor #biology. ❕ These results highlight the importance of continued research into #biomarkers and tailored therapies, especially for subtypes like lobular breast cancer, which may benefit from specific treatment approaches. A big thank you to all collaborators for making this trial possible. Looking forward to more insights and discussions 🤗 Find the poster presentation on our website: https://lnkd.in/ekUTeVRn Pfizer GBG Forschungs GmbH #breastcancer #oncology #clinicaltrials #palbociclib #ESMO #personalizedmedicine #GBG

🔬 Exciting News from Clinical Cancer Research! 🔬 We're thrilled to share an editorial comment has been published in Clinical Cancer Research (https://lnkd.in/dFTqVvuq) regarding our recent publication (https://lnkd.in/dhWKEwe3) on TILT-123 used as monotherapy in a Phase I trial! Independent experts in the field have highlighted the promising results of our study, which tested an oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 in patients with advanced solid tumors. The authors concluded that "TILT-123 seems to be a promising candidate to join the still short list of approved oncolytic viruses," underscoring the significance of our findings in advancing cancer treatment. This recognition highlights our commitment to advancing innovative therapies in oncology and bringing hope to patients facing challenging conditions. This type of research is conditional to the patients who volunteer to advance cancer treatment, a big thank you them! Also to our dedicated team and collaborators for their hard work and expertise! #ClinicalTrial #OncolyticVirotherapy #CancerResearch #InnovationInMedicine #ClinicalCancerResearch

😀 Folate receptor alpha (FRα) is considered an ideal drug-forming target due to its differential expression in a variety of tumors or cancerous and normal tissues. #News 🎉 AbbVie posted topline results from the Phase II trial, demonstrating the therapeutic potential of its newly acquired antibody-drug conjugate Elahere from ImmunoGen in folate receptor-alpha-positive, platinum-sensitive ovarian cancer. Elahere met its primary efficacy endpoint, eliciting a 51.9% objective response rate in heavily pretreated patients. Elahere is a first-in-class ADC designed to target the FRα, which is highly expressed in ovarian malignancies. 👉Check out our FRα catalog: https://lnkd.in/gdxitXfR 📧 mkt.genomeditech@gmail.com #celllinedevelopment #cancertreatment #drugdiscovery #FRα #CancerResearch #Immunotherapy #CancerTherapy #ADC

New!🦞 Circulating interleukin-8 and #osteopontin are promising biomarkers of clinical outcomes in advanced #melanoma patients treated with targeted therapy ------------------- Circulating cytokines can represent non-invasive biomarkers to improve prediction of clinical outcomes of cancer patients. In this study by Stefania D'Atri et al plasma levels of IL-8, CCL4, osteopontin, LIF and BDNF were determined at baseline (T0), after 2 months of therapy (T2) and, when feasible, at progression (TP), in 70 melanoma patients treated with BRAF and MEK inhibitors. The association of baseline cytokine levels with clinical response, progression-free survival (PFS) and overall survival (OS) was evaluated. Look here👇 https://lnkd.in/dE3cn4qW #CirculatingCytokines #Survival IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Online!🏖️ Integrin-linked kinase-frizzled 7 interaction maintains #cancerstemcells to drive #platinumresistance in #ovariancancer --------------------- Platinum-based chemotherapy regimens are a mainstay in the management of ovarian cancer (OC), but emergence of chemoresistance poses a significant clinical challenge. The persistence of ovarian cancer stem cells (OCSCs) at the end of primary treatment contributes to disease recurrence. Here, Salvatore Condello et al. hypothesized that the extracellular matrix protects CSCs during chemotherapy and supports their tumorigenic functions by activating integrin-linked kinase (ILK), a key enzyme in drug resistance. For free👇 https://lnkd.in/dBPxks8J #Chemoresistance #Tumormicroenvironment IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano